Mangalam Drugs and Organics share news, announcements and annual reports
NSE: MANGALAMBSE: 532637Pharmaceuticals & BiotechnologySmall Cap
Mangalam Drugs and Organics Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 2005
Last close ₹28.61down ₹0.61 (2.09%)BSE ₹28.92
Share price at the NSE close on 30 Oct 2026. Previous close ₹29.22.
30 Oct: open ₹29.48, high ₹29.75, low ₹28.51
52-week range of traded prices to 30 Oct 2026
₹22.80Low, 29 Dec 2025₹68.40High, 30 Oct 2025
- Under NSE's long-term additional surveillance, stage I, on the list for 30 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Next results date: the board meets on 5 Nov 2026 to consider: financial results and other business matters. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹45 Cr3,423rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 0.44
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −30.3%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −12.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 1.02
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 50,07391.9% delivered
Mangalam Drugs and Organics disputes and clarifications
34 filed, newest first.
Oct 2026
16 Oct · Legal
Sep 2026
15 Sep · Legal
Aug 2026
17 Aug · Legal
Jul 2026
16 Jul · Legal
Jun 2026
17 Jun · Legal
May 2026
16 May · Legal
Apr 2026
16 Apr · Legal
Mar 2026
17 Mar · Legal
Feb 2026
Jan 2026
7 Jan · Legal
The exchange asked on 5 Jan 2026
Dec 2025
19 Dec · Legal
Nov 2025
18 Nov · Legal
Jan 2024
Dec 2023
12 Dec · Legal
Exchange has sought clarification from Mangalam Drugs And Organics Limited for the quarter ended 30-Sep-2023 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Statement of Cash Flow not submitted The response of the Company is awaited.
Jul 2021
12 Jul · Legal
Exchange has sought clarification from Mangalam Drugs And Organics Limited with respect to announcement dated 05-Jul-2021, regarding Resignation of Statutory Auditor. On basis of above the Company is required to provide details w.r.t Annexure A of the SEBI Circular CIR/CFD/CMD1/114/2019 dated October18,2019. The response of the Company is awaited.
Dec 2020
17 Dec · Legal
Exchange has sought clarification from Mangalam Drugs And Organics Limited with respect to announcement dated 07-Dec-2020, regarding "Resignation of Mr Prashant J Pandit as Non- Executive Independent Director of the company w.e.f. December 02, 2020."On basis of above the Company is required to clarify following:1. No other material reasons other than providedThe response of the Company is awaited.
Sep 2020
14 Sep · Legal
Exchange has sought clarification from Mangalam Drugs And Organics Limited for the quarter ended 30-Jun-2020 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Limited Review Report/ Independent Auditor's Report is not in the format prescribed by SEBI The response of the Company is awaited.
Aug 2020
14 Aug · Legal
Exchange has sought clarification from Mangalam Drugs And Organics Limited with respect to announcement dated 10-Aug-2020, regarding appointment of C.S. Ajgaonkar & Co. - Chartered Accountants as Internal Auditors of the Company. On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment). The response of the Company is awaited.
Dec 2019
Nov 2019
21 Nov · Legal
Exchange has sought clarification from Mangalam Drugs And Organics Limited for the quarter ended 30-Sep-2019 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
Jul 2019
22 Jul · Legal
The exchange asked on 22 Jul 2019
19 Jul · Legal
Exchange has sought clarification from Mangalam Drugs And Organics Limited with respect to announcement dated 08-Jul-2019, about the following changes: 1. Resignation of Ms. Nikita Bavishi as Company Secretary & Compliance officer of the company w.e.f. closure of business hours of 08th July, 2019. 2. Appointment of Ms. Geeta G. Karira as Company Secretary & Compliance officer of the company w.e.f. 09th July, 2019. On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment). The response of the Company is awaited.
Feb 2019
14 Feb · Legal
Significant movement in price has been observed in Mangalam Drugs And Organics Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.
Dec 2017
28 Dec · Legal
The exchange asked on 27 Dec 2017
Mar 2015
19 Mar · Legal
Price movement : Significant price movement has been observed in Mangalam Drugs And Organics Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Mangalam Drugs And Organics Limited has vide its letter inter-alia stated,"The Company has no pending announcements to make having a bearing on operation/performance of the Company or which may result in unusual price/volume behavior of the stock price."